Recent Events - The control change plan has been terminated as of January 7, 2026, due to the failure of the controlling shareholder and the counterparty to reach an agreement, leading to stock resumption and subsequent price fluctuations. This matter is not expected to have a significant adverse impact on the company's operations, which remain normal [1]. Performance Overview - For the period from January to September 2025, the company achieved a revenue of 299 million yuan, representing a year-on-year growth of 2.74%. The net profit attributable to shareholders was 32.67 million yuan, reflecting a year-on-year increase of 36.41%. The company emphasized its core business in small molecule generic drugs, with project applications and approvals ranking among the industry leaders [2]. Stock Performance - As of February 13, 2026, the stock price of the company was 9.32 yuan per share, with a total market capitalization of 3.584 billion yuan. The stock has seen a cumulative decline of 23.86% this year, although it has increased by 1.53% in the last five trading days. On that day, there was a net inflow of 6.07 million yuan in principal funds, with a turnover rate of 0.98%. The company has appeared on the stock leaderboard four times this year, with the most recent occurrence on January 13 [3]. Company Status - In April 2025, the indirect controlling shareholder, Hualing Industrial Trade, was changed to a state-owned enterprise in Xinjiang, with Xinjiang Commercial and Material Asset Management Co., Ltd. holding 51% of the shares, ultimately supervised by the Xinjiang State-owned Assets Supervision and Administration Commission. This change may affect the company's long-term strategy. Currently, there are no other significant announcements from the company, but investors are advised to pay attention to regular financial reports and any official disclosures regarding control dynamics [4].